Osteoblast-derived TGF-β1 modulates matrix degrading protease expression and activity in prostate cancer cells

International Journal of Cancer

Volumn 85, Issue 3, 2000, Pages 407-415

  Festuccia, Claudio ^a,c   Angelucci, Adriano ^a   Gravina, Giovanni Luca ^a   Villanova, Ida ^a   Teti, Anna ^a   Abini, Adriana ^b   Bologna, Mauro ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b ADVANCED BIOTECHNOLOGY CENTER   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINASE; TRANSFORMING GROWTH FACTOR BETA1; UROKINASE; ANTINEOPLASTIC AGENT; BIOMATERIAL; COLLAGEN; LAMININ; MATRIGEL; MEMBRANE PROTEIN; PROTEINASE INHIBITOR; PROTEOGLYCAN; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVITY; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TUMOR GROWTH; ANIMAL; BIOSYNTHESIS; BONE TUMOR; CANCER INVASION; CELL CULTURE; CULTURE MEDIUM; DISEASE COURSE; DRUG COMBINATION; DRUG EFFECT; ENZYMOLOGY; EXTRACELLULAR MATRIX; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; HUMAN; MALE; METABOLISM; METASTASIS; PATHOLOGY; PROSTATE TUMOR; RABBIT; SERODIAGNOSIS; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOCOMPATIBLE MATERIALS; BLOTTING, WESTERN; BONE NEOPLASMS; COLLAGEN; CULTURE MEDIA, CONDITIONED; DISEASE PROGRESSION; DRUG COMBINATIONS; ENDOPEPTIDASES; EXTRACELLULAR MATRIX; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LAMININ; MALE; MATRIX METALLOPROTEINASE 9; MEMBRANE PROTEINS; NEOPLASM INVASIVENESS; OSTEOBLASTS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRECIPITIN TESTS; PROSTATIC NEOPLASMS; PROTEASE INHIBITORS; PROTEOGLYCANS; RABBITS; TISSUE INHIBITOR OF METALLOPROTEINASES; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 0033621749     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(20000201)85:3<407::AID-IJC18>3.0.CO;2-8     Document Type: Article

References (33)

1. ALBINI, A., IWAMOTO, Y., KLEINMAN, H.K., MARTIN, G.R., AARONSON, S.A., KOZLOSWKI, J.N. and MCEWAN, R.N., A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res. 47, 3239-3245 (1987).
2. ALBO, D., ARNOLETTI, J.P., CASTIGLIONI, A., GRANICK, M.S., SOLOMON, M.P., ROTHHMAN, V.L. and TVUSZYNSKI, G.P., Thrombospondin (TSP) and transforming growth factor beta 1 (TGF-β) promote human A549 lung carcinoma cell plasminogen activator type 1 (PAI-1) production and stimulate tumor cell attachment in vitro. Biochem. biophys. Res. Comm., 203, 857-865 (1994).
3. ANDREASEN, P.A., KJOLLER, L., CHRISTENSEN, L. and DUFFY, M.J., The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer, 72, 1-22 (1997).
4. ARNOLETTI, J.P., ALBO, D., GRANICK, M.S., SOLOMON, M.P., CASTIGLIONI, A., ROTMAN, B.S. and TUSZYNSKI, G.P., Thrombospondin and transforming growth factor beta1 increase expression of urokinase type plasminogen activator and plasminogen activator inhibitor 1 in human MDA-MB 231 breast cancer cells. Cancer, 76, 998-1500 (1995).
5. BARRACK, E.R., TGF-β in prostate cancer: a growth inhibitor that can enhance tumorigenicity. Prostate, 31, 61-70 (1997).
6. BONEWALD, L.F., Regulation and regulatory activities of transforming growth factor β. Crit. Rev. Eukaryotic Gene Expression, 9, 33-44 (1999).
7. BONEWALD, L.F. and DALLAS, S., Role of active and latent transforming growth factor-β in bone formation. J. Cell. Biochem., 55, 350-357 (1994).
8. COTTAM, D.W. and REES, R.C., Regulation of matrimetalloproteinases: their role in tumor invasion and metastasis (review). Int. J. Oncol., 2, 861-872 (1993).
9. DANØ, K., ANDREASEN, I.A., GRØNDHAL-HANSEN, J., KRISTENSEN, P., NIELSEN, L.S. and SKRIVER, L., Plasminogen activators tissue degradation and cancer. Adv. Cancer Res., 44, 139-266 (1985).
10. FARINA, A.R., COPPA, A., TIBERIO, A., TACCONELLI, A., TURCO, A., COLLETTA, G., GULINO, A. and MACKAY, A.R., Transforming growth factor beta1 enhances the invasiveness of human MDA-MB 231 breast cancer cells up-regulating urokinase activity. Int. J. Cancer, 75, 721-730 (1998).
11. FESTUCCIA, C., VICENTINI, C., FIRMA, N., ACETO, G., ZAZZERONI, F. and BOLOGNA, M., Plasminogen activator activities in short-term tissue cultures of benign prostatic hyperplasia and prostatic carcinoma. Oncol. Res., 7, 131-138 (1995).
12. FESTUCCIA, C., DOLO, V., GUERRA, F., VIOLINI, S., MUZI, P., PAVAN, A. and BOLOGNA, M., Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells. Clin. exp. Metastasis, 16, 513-528 (1998).
13. FESTUCCIA, C., BOLOGNA, M. GRAVINA, G.L., GUERRA, F., ANGELUCCI, A., VILLANOVA, I., MILLIMAGGI, D. and TETI, A., Osteoblast conditioned media contain TGF-β1 and modulate the migration of prostate tumor cells and their interactions with extracellular matrix components. Int. J. Cancer, 81, 395-403 (1999a)
14. FESTUCCIA, C., GIUNCIUGLIO, D., GUERRA, F., VILLANOVA, I., ANGELUCCI, A., MANDUCA, P., TETI, A., ALBINI, A. and BOLOGNA, M., Osteoblasts modulate secretion and activation of urokinase type plasminogen activator (uPA) and matrix metalloproteinase-9 (MMP-9) in human prostate cancer cells promoting migration and Matrigel invasion. Oncol. Res., 11, 17-31 (1999b)
15. FOEKENS, J.A., SCHMITT, M., VAN PUTTEN, W.L.J., PETERS, H.A., BONTEBAL, M., JÄNICKE, F. and KLIJN, J.G.M., Prognostic value of urokinase type plasminogen activator in 671 primary breast cancer patients. Cancer Res., 52, 6101-6105 (1992).
16. GEHRON-ROBEY, P., YOUNG, M.F., FLANDERS, K.C., ROCHE, N.S., KONDAIAH, P., REDDI, A.H., TERMINE, J.D., SPORN, M. B. and ROBERTS, A.B., Osteoblasts synthesize and respond to transforming growth factor type b in vitro. J. Cell. Biol., 105, 457-463 (1987).
17. HOSOKAWA, T., MURAISHI, A. ROTHMAN, W.L., PAPALE, M. and TUSZYNSKI, G.P., The effect of trombospondin on invasion of fibrin gels by human A549 lung carcinoma. Oncol. Res., 5, 183-189 (1993).
18. JÄNICKE, F., SCHMITT, M. and GRAEFF, H., Clinical relevance of urokinase type and tissue type plasminogen activators and their type 1 inhibitor breast cancer. Semin. Thrombosis Hemostasis, 17, 303-332 (1991).
19. KESKI-OJA, J., BLASI, F., LEOF, E.B. and MOSES, H.L., Regulation of the synthesis and activity of urokinase plasminogen activator in A549 human lung carcinoma cells by transforming growth factor beta. J. Cell. Biol., 106, 451-459 (1988).
20. KYPRIANOU, N., ENGLISH, H.F. and ISAACS, J.T., Programmed cell death during regression of PC82 human prostate cancer following androgen ablation. Cancer Res., 50, 3748-3753 (1990).
21. LIOTTA, L.A., STEEG, P.S. and STETLER-STEVENSON, W.G., Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 64, 327-336 (1991).
22. LUND, L.R., ELLIS, V., RONNE, E., PYKE, C. and DANØ, K., Transcriptional and post-transcriplional regulation of the receptor for urokinase type plasminogen activator by cytokines and tumor promoters in the human lung carcinoma cell line A549. Biochem. J., 310, 345-352 (1995).
23. MANN, E.A., HIBBS, M.S., SPIRO, J.D., BOWIK, C., WANG, X.Z., CLAWSON, M. and CHEN, L.L., Cytokines regulation of gelatinase production by head and neck squamous cell carcinoma: the role of tumor necrosis factor-alpha. Ann. Otol. Rhinol. Laryngol., 104, 203-209 (1995).
24. MATRISIAN, L.M., GANSER, G.L., KERR, L.D. and WOOD, L.D., Negative regulation of gene expression by TCP-beta. Mol. Reprod. Develop., 32, 111-120 (1992).
25. MORTON, D.M. and BARRACK, E.R., Modulation of transforming growth factor β1 effects on prostate cancer cell proliferation by growth factors and extracellular matrix. Cancer Res., 55, 2596-2602 (1995).
26. OVERALL, C.M., WRANA, J.L. and SODEK, J.J., Independent regulation of collagenase, 72kDa progelatinase and metalloendoproteinase inhibitor expression in human fibroblasts by transforming growth factor beta. J. biol. Chem., 264, 1860-1869 (1989).
27. RAK, J.W. and KERBEL, R.S., Growth advantage ("clonal dominance") of metastatically competent tumor cell variants expressed under selective two-or three-dimensional tissue culture conditions. In Vitro Cell. Develop. Biol Animal., 29, 742-748 (1993).
28. STAHL, A. and MUELLER, B.M., Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res., 54, 3066-3071 (1994).
29. STEINER, M.S., ZHOU, Z.Z., TONB, D.C. and BARRACK, E.R., Expression of transforming growth factor beta1 in prostate cancer. Endocrinology, 135, 2240-2247 (1994).
30. TETI, A., DE GIORGI, A., SPINELLA, M.T., MIGLIACCIO, S., CANIPARI, R., ONETTI MUDA, A. and FARAGGIANA, T., Transforming growth factor-beta enhances adhesion of melanoma cells to the endothelium in vitro. Int. J. Cancer, 72, 1013-1020 (1997)
31. TOTH, M., GERVASI, D.C. and FRIDMAN, R., Phorbol esther-induced cell surface association of matrix metalloproteinase-9 in human MCF10A breast epithelial cells. Cancer Res., 57, 3159-3167 (1997).
32. WILDING, G., ZUGMEIER, G., KNABBE, C., FLANDERS, K. and GELMANN, E., Differential effects of transforming growth factor-β on human prostate cancer cells in vitro. Mol. cell. Endocrinol., 62, 79-87 (1989).
33. YEE, J.A., YAN, L., DOMINGUEZ, J.C., ALLAN, E.H. and MARTIN, T.J., Plasminogen-dependent activation of latent transforming growth factor beta (TGF-β) by growing cultures of osteoblast-like cells. J. cell. Physiol., 157, 528-534 (1993).